Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 StudyDefense World · Oct 15, 2026
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 StudyMarketBeat · Oct 13, 2026
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss TranscriptSeeking Alpha · Oct 13, 2026
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor AgonistGlobeNewsWire · Oct 13, 2026
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor AgonistGlobeNewsWire · Oct 12, 2026
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study DataBenzinga · Sep 23, 2026Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.22 | -$0.12 | Beat |
| May 11, 2026 | -$0.24 | -$0.17 | Beat |
| Mar 24, 2026 | -$0.25 | -$0.64 | Miss |
| Nov 4, 2025 | -$0.26 | -$0.27 | Miss |
| Aug 5, 2025 | -$0.59 | -$0.51 | Beat |
| May 5, 2025 | -$0.84 | -$0.80 | Beat |